Every material Form 8-K MiniMed Group, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MiniMed completed its exchange offer with Medtronic on October 15, 2026, and Medtronic no longer holds any MiniMed common stock. The same day, four directors resigned from the MiniMed board, and Amy Bricker was appointed to fill one vacancy as the board was reduced from 11 to eight seats.
Medtronic accepted 55,032,401 Medtronic ordinary shares in exchange for 252,813,348 newly issued MiniMed common shares; the offer was 5.4x subscribed.
Medtronic no longer owns any MiniMed common stock, and MiniMed states it is now a fully independent company.
Linnea Burman, Scott Cundy, Laura Mauri and Matthew R. Walter resigned from the board effective October 15, 2026; Amy Bricker joined as a Class II director.
MiniMed reported first-quarter fiscal 2027 net sales of $843 million, up 16.6% from $723 million a year earlier, and reported net income of $0 compared with a loss of $16 million. The company raised its fiscal 2027 organic revenue growth guidance to approximately 10.5% from approximately 10%, while reaffirming its adjusted EBITDA margin guidance of approximately 16%.
Net sales were $843 million vs. $723 million; U.S. net sales grew 13.1% to $240 million and international grew 18.1% to $603 million.
Net income attributable to the company was $0 (EPS $0.00) vs. a loss of $19 million (EPS -$0.08) a year earlier.
FY27 organic revenue growth guidance raised to approximately 10.5% from approximately 10%; the figure includes a 1.0% to 1.5% benefit from an extra week in Q1.
Adjusted EBITDA margin guidance of approximately 16% was reaffirmed; a $2 million litigation benefit was recorded vs. a $17 million charge a year earlier.
MiniMed Group's senior vice president, general counsel and corporate secretary, Courtney Nelson Wills, has resigned after an eight-week transition period, with her departure effective September 25, 2026. The company says the exit is for personal reasons, not a disagreement, and that it is searching for a successor.
Courtney Nelson Wills notified MiniMed of her resignation on July 30, 2026
Resignation takes effect September 25, 2026, after an 8-week transition period
She is leaving to take a role outside the medical device space; the filing cites no disagreement with MiniMed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MiniMed Group, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →